Sling raises $123M to push oral thyroid-eye-disease drug into Phase 3 on September 16, 2026 Forbion IGF1R protein, human Linsitinib NALF2 gene ORBIT trial Phase 3 Series C Sling Therapeutics Tepezza Thyroid associated opthalmopathies +
Lumvoa emerges as strong Tepezza rival—but SC Tepezza looms on the horizon on July 09, 2026 Amgen Approved IGF1R protein, human Lumvoa subcutaneous Tepezza Thyroid associated opthalmopathies United States Food and Drug Administration Viridian +
Ethyreal Bio emerges with $101M to challenge Amgen’s Tepezza in thyroid eye disease on June 10, 2026 Amgen Amgen 's anti-TSHR antibody Avoro Capital Cervical Atlas Ethyreal Bio Graves Disease Tepezza Thyroid associated opthalmopathies venture +